← Surfer · Sage hub

Sage — Metabolic Hypothesis of Dermatology

Hair and skin are not merely decorative surfaces. Their color, density, diameter, luster, texture, barrier integrity, regional patterning, and neoplastic potential are among the most visible, costly, and condition-dependent signals an organism can display. Pigmented, full, resilient hair and clear, elastic, well-perfused skin require continuous high-flux melanogenesis, rapid keratinocyte proliferation, precise melanosome transfer, robust fibroblast collagen turnover, and stem-cell maintenance. These processes are energetically expensive. When cellular ATP-generating capacity falls short of demand, the system does not fail randomly. It prioritizes. The most energy-demanding follicular and dermal units are the first to sacrifice non-essential outputs—beginning with pigmentation, diameter, and high-turnover remodeling. At the extreme of the same hierarchy, when the mismatch is severe and sustained, the system can shift into a primitive survival program that, under selection, produces the full neoplastic phenotype.

This is the metabolic hypothesis of dermatology. The degree of mismatch between mitochondrial ATP capacity and local cellular load determines where compensatory savings are concentrated and, when the deficit is profound, where the two-step process of carcinogenesis is initiated. The same logic that governs the progressive loss of ATP-generating capacity across the organism (the metabolic hypothesis of aging), the honest signaling of surplus energy as beauty (the metabolic hypothesis of beauty), and the upstream energy crisis that enables cancer (the mitochondrial-metabolic hypothesis of cancer) applies with particular clarity to the hair follicle, epidermis, dermis, and their neoplastic transformations.

Energy Hierarchy and Regional Sacrifice

Melanocytes within the anagen hair-follicle pigmentary unit are among the most metabolically active cells in the integument. Melanin synthesis itself is an oxidative process that generates reactive intermediates, and gray hair shafts accumulate hydrogen peroxide; the cells must simultaneously produce pigment and neutralize the by-products while supporting dendrite extension and melanosome transfer. Follicular keratinocytes during rapid growth phases impose additional high ATP demand. When systemic or local mitochondrial capacity declines—reduced biogenesis, impaired mitophagy, rising heteroplasmy, substrate inflexibility, or chronic redox strain—the follicle begins to shed costly functions in a ranked order.

Pigmentation is near the top of the expendable list. It is not required for the mechanical integrity of the hair shaft or for the basic cycling of the follicle. It is, however, a high-visibility signal of energetic surplus. Under constraint, the system conserves ATP by down-regulating tyrosinase activity, impairing melanosome transfer, and eventually depleting the local melanocyte and melanocyte-stem-cell populations. The result is progressive canities; in mice and humans, incomplete maintenance of melanocyte stem cells in the follicle niche underlies age-related graying.

Regional patterning follows the same energy logic. Facial and temporal follicles, and those in high-visibility, high-turnover zones of the scalp, may operate under greater chronic demand or tighter coupling to systemic metabolic state. These sites often gray first. Temples and frontal regions commonly precede the vertex or occipital scalp in many individuals. Less metabolically demanding or more protected follicular fields retain pigment longer. The same hierarchy appears in patterned hair loss: temples and vertex thin preferentially when androgen sensitivity intersects with underlying energetic shortfall. The androgen receptor and downstream pathways may modulate local demand or vascular support, but the decision to abandon maintenance is still governed by whether residual ATP capacity can meet the load.

Hair thickness, tensile strength, growth rate, sebum quality, and overall fullness follow the identical principle. These traits require continuous investment in keratin synthesis, lipid metabolism, and matrix remodeling. When the energy budget tightens, diameter decreases, the anagen phase shortens, and the follicle produces finer, more brittle, or fewer hairs. Parallel processes occur in the epidermis and dermis: reduced fibroblast ATP limits collagen and elastin turnover, impaired endothelial mitochondrial function reduces perfusion and glow, and barrier lipids become less optimally organized. The visible phenotype is not primarily a “genetic program of aging” unfolding on a fixed timetable; it is the cumulative map of where compensatory load savings have been applied.

It helps to be precise about where this energy is spent. The hair shaft above the skin is not living tissue. As I read the evidence, it is a column of dead, keratin-packed cells with no active metabolism of its own. The change from living to dead cells happens low in the follicle, near the bulb, in the keratogenous zone; one group working with human scalp tissue places the whole transition within roughly the first 1 mm of hair formation. In their model the steps run in order. The nucleus is broken down first. The cell then appears to keep respiring for a brief phase without a nucleus, and the reactive oxygen species from that leftover mitochondrial activity may help cross-link the keratin. Last, the mitochondria themselves are cleared by mitophagy, driven by the receptor Bnip3L (also called NIX). An earlier electron-microscopy study saw nuclei and mitochondria disappear at about the same level of the shaft, so the exact order is still open.

The living follicle is a different matter. In freshly isolated human follicles, most glucose is turned into lactate rather than fully oxidized, a pattern called aerobic glycolysis, and glutamine serves as an important second fuel. In mouse studies, the stem cells that start each new growth phase appear to depend on lactate production to wake up; their descendants shift toward oxidative metabolism and glutamine use as they commit to building the follicle; and reactive oxygen species from mitochondria act as a signal needed for normal follicle development. Imaging of cultured cow follicles and plucked human hairs found active, ROS-producing mitochondria throughout the lower bulb, brightest in a band around the forming cuticle and outer cortex that the authors called a “ring of fire”. Just above it, mitochondrial activity switches off abruptly where the shaft begins.

This is why I do not think of the shaft as anything like a nerve axon. An axon is a living extension of a living cell: it holds mitochondria along its whole length and depends on constant transport to and from the cell body to keep them healthy. The hair shaft has no such traffic. It is a finished product pushed out from below. Two practical points follow. Cutting or shaving the shaft does not appear to stimulate the follicle; small controlled studies of beard and leg shaving in men found no change in growth rate or hair width. (Clipping has been reported to trigger a new growth phase in some rodents, so the human result should not be stretched to every mammal.) And ordinary shampoos and conditioners act on surfaces: they clean, lubricate and smooth the cuticle of the shaft, and shampoo also cleans the scalp, but they are not designed to change the metabolism of the bulb deep in the skin.

In my reading this sharpens the hypothesis rather than complicating it. Everything this essay treats as costly (pigment, diameter, growth rate and strength) is paid for in the living follicle before the shaft leaves the skin. The shaft is best seen as a record of the follicle’s energy budget at the time each segment was made, not a tissue that can be fed or starved afterward. If that is right, the place to look for change is the follicle’s energy supply, not the fiber.

Correlation with Broader Skin and Systemic Load Failure

If the hypothesis is correct, graying and patterned thinning should not travel alone. They should co-vary with other signs that the skin’s energy economy is failing to meet demand. Acne-prone or persistently inflamed skin, dull or uneven complexion, accelerated dermal thinning and wrinkling, impaired barrier function, and reduced glow all reflect the same upstream constraint: insufficient ATP and redox capacity relative to the continuous requirements of fibroblast collagen turnover, endothelial perfusion, and epidermal renewal. These are not separate “skin problems.” They are parallel readouts of the same mismatch.

Downstream autoimmune and inflammatory phenotypes fit the same framework. On this hypothesis, vitiligo, alopecia areata, and certain forms of rosacea can be understood as later or more extreme expressions of bioenergetic failure in melanocyte or follicular niches; cultured vitiligo cells do show impaired mitochondrial energy production. When mitochondrial quality control collapses, mtDAMPs rise, local inflammatory tone increases, and immune surveillance or auto-reactivity can target the already stressed cell populations. The visible result is focal pigment loss or hair loss that appears “autoimmune,” yet the initiating condition is often chronic energy insufficiency that rendered those cells vulnerable. Patterned androgenetic alopecia itself frequently co-travels with metabolic risk markers—insulin resistance, visceral adiposity, elevated blood pressure—which on this hypothesis is consistent with a systemic ATP shortfall that is simply expressed most visibly in the hair-bearing skin of the scalp.

Unifying Power

The metabolic hypothesis of dermatology is not an isolated claim. It is a direct application of the same single upstream variable that organizes the metabolic hypotheses of aging, beauty, atherosclerosis, cancer, and related chronic phenotypes: net cellular ATP output relative to demand. Oxidative damage, epigenetic drift, hormonal shifts, and genetic predisposition remain real. On this hypothesis, they are largely downstream amplifiers or local modulators of the primary constraint. Melanocyte stem-cell exhaustion, elevated intrafollicular mTORC1 activity, hydrogen-peroxide accumulation, defective melanosome transfer, impaired dermal matrix turnover, and the initiation of neoplastic transformation are observable mechanisms; each becomes more probable when the mitochondrion can no longer supply the ATP and reducing power required for faithful maintenance, repair, and cooperative multicellular behavior.

Several comparative and experimental observations are read here as aligned. Mitochondrial DNA maintenance defects produce premature hair loss and other ageing signs in mice and are proposed to cause premature graying via ROS-driven melanocyte-stem-cell loss. Systemic mtDNA depletion in mice induces hair loss and wrinkled, inflamed skin that reverse when mitochondrial function is restored. Premature graying correlates with metabolic risk factors such as obesity, and with smoking, even in younger cohorts. On this hypothesis, these data are more parsimoniously explained by energy hierarchy than by purely chronological or purely genetic models.

Plasticity, Reversibility, and Limits under Metabolic Restoration

The hypothesis predicts that pigment, diameter, density, quality, and dermal matrix integrity are condition-dependent outputs. When ATP-generating capacity is restored relative to local demand, the system should regain the capacity to invest in previously sacrificed functions—provided the cellular infrastructure that produces those functions still exists. Evidence suggests meaningful plasticity in early-to-intermediate stages and clearer permanence once critical stem-cell or structural thresholds are crossed.

Individual human hairs can gray and then fully repigment. Quantitative hair-pigmentation-pattern mapping has documented complete reversal of white segments to the original color in the same shaft, temporally aligned with reduction in psychological stress. Gray hairs themselves upregulate mitochondrial, energy-metabolism, and antioxidant proteins, possibly consistent with a compensatory response rather than irreversible death of the pigmentary unit. In organ-cultured human scalp follicles, mTORC1 inhibition restimulates melanogenesis, gp100 expression, tyrosinase activity, and melanocyte dendricity even in gray follicles that retain residual melanocytes; the same intervention prolongs anagen and thereby widens the window during which repigmentation can occur.

Nutrient repletion produces the clearest clinical reversals. A systematic review links premature graying with B12 deficiency and reports reversal in many cases once the accompanying condition is treated. Mitochondrial models reinforce the point: ROS scavenging after mtDNA disruption restores melanocyte-stem-cell numbers and reduces depigmentation in mice. Dietary restriction and senolytic treatment mitigated premature hair-follicle aging (graying and loss) in an IGF-1-driven mouse model. Parallel improvements in dermal thickness, elasticity, and barrier function occur when mitochondrial capacity is restored. These data suggest that melanogenesis, local melanocyte function, and fibroblast matrix production remain plastic when the energetic and redox constraints are lifted before irreversible stem-cell or structural loss.

Follicular miniaturization is not an all-or-none switch. Insulin resistance has been associated with early androgenetic alopecia, and metabolic syndrome appears more common with more severe hair loss, though a causal direction has not been established; on this hypothesis, elevated fasting insulin increases local androgen signaling and inflammatory tone that accelerate the transition from terminal to intermediate and vellus hairs. Improving insulin sensitivity, reducing chronic low-grade inflammation, and restoring fuel flexibility are therefore predicted to slow or partially reverse miniaturization while the dermal papilla and follicular stem-cell niche remain competent. Resistance training and adequate protein support the hormonal and growth-factor milieu that favor larger shaft diameter and longer anagen. Quality metrics—luster, tensile strength, reduced breakage, dermal thickness, and glow—track collagen and keratin synthesis capacity, both ATP- and redox-dependent.

Systemic metabolic optimization also lowers the inflammatory set-point that amplifies follicular and melanocyte-targeted autoimmunity. Low-glycemic and ketogenic patterns may reduce NLRP3 inflammasome activity and oxidative stress; the ketone beta-hydroxybutyrate blocks NLRP3 activation in mouse and human cells. Alopecia areata and vitiligo frequently co-travel with metabolic comorbidities; addressing insulin resistance, visceral adiposity, and micronutrient gaps may reduce the chronic inflammatory drive that sustains immune attack on already energy-stressed follicles and melanocytes. The effect, on this hypothesis, is adjunctive rather than curative, yet clinically relevant: fewer flares, slower progression, and improved response to conventional therapies once the bioenergetic substrate is stabilized.

Plasticity has clear boundaries. Once bulge melanocyte stem cells are depleted, the pigmentary unit cannot be reconstructed in subsequent cycles; graying becomes effectively irreversible for that follicle. Prolonged gray/white status without residual melanocytes marks the same threshold. Advanced androgenetic miniaturization that has progressed to permanent vellus conversion or follicular dropout with fibrosis leaves little substrate for regrowth. Extensive dermal matrix loss and advanced photoaging similarly constrain full structural recovery. Metabolic restoration can stabilize remaining follicles and improve quality of residual hair and skin, but cannot resurrect lost units or fully reverse long-standing fibrotic change. Genetic predisposition sets the ceiling: optimization moves the phenotype toward the individual’s genetic maximum; it does not erase the androgen-receptor sensitivity or stem-cell reserve constraints written in the genome.

Extreme or poorly timed interventions can also limit plasticity. Severe caloric restriction or prolonged intermittent fasting can raise lipolytic free-fatty-acid flux and oxidative stress. In mice, intermittent fasting released free fatty acids into the follicle niche and induced apoptosis in activated hair-follicle stem cells, an effect the authors found independent of calorie reduction, and a small randomized trial found slower human hair growth; regrowth may slow even while systemic metabolic markers improve. The therapeutic window therefore favors gradual restoration of ATP capacity—adequate protein and micronutrients, circadian coherence, progressive resistance loading—rather than abrupt energy deficit.

Androgen Modulation as Downstream Compensation

Conventional dermatology treats androgenetic alopecia primarily by modulating androgen signaling: 5α-reductase inhibitors (finasteride, dutasteride), androgen-receptor antagonists (spironolactone, topical anti-androgens), and related agents. These interventions demonstrably slow miniaturization and can produce modest regrowth in many patients. Within the metabolic philosophy of medicine they are understood as interventions directed at a downstream compensatory amplifier rather than at the primary constraint—the mismatch between ATP-generating capacity and follicular demand.

How Androgen Changes Function as Compensation

Under progressive loss of mitochondrial ATP capacity, cells and tissues enter chronic compensatory mode. One systemic expression of this mode is the hormonal milieu of insulin resistance and low-grade inflammation. Hyperinsulinemia suppresses hepatic SHBG production, raising free testosterone and the substrate available for local conversion to DHT. Adrenal and ovarian androgen output can also increase as part of broader stress and thrifty responses to energetic shortfall. The result is elevated free androgen tone that is not primarily “too much testosterone for its own sake,” but a secondary consequence of the organism’s attempt to maintain reproductive and anabolic signaling while operating under constrained energy yield.

Locally in genetically predisposed follicles, DHT binding to the androgen receptor accelerates the energy-triage process already underway. It shortens anagen, elevates TGF-β and other inhibitory signals, reduces dermal-papilla support, and promotes the progressive conversion of terminal follicles toward intermediate and vellus states. In metabolic terms this may be further load-shedding: the follicle reduces its energetic commitment (smaller matrix, shorter growth phase, less pigment and keratin investment) under the dual pressure of limited ATP and amplified androgen signaling. The androgen pathway does not create the energy deficit; it magnifies the consequences of that deficit in androgen-sensitive scalp regions. On this hypothesis, temples and vertex are preferentially affected because they combine high baseline metabolic demand with heightened androgen-receptor density or 5α-reductase activity.

On this hypothesis, androgen-driven miniaturization is a compensatory downsizing program. It is adaptive in the narrow sense that it reduces the ATP cost of maintaining large, rapidly cycling follicles when systemic or local energy supply is inadequate. It is maladaptive in the broader sense that it permanently sacrifices a costly honest signal of fitness and can progress to irreversible follicular dropout.

Limitations of Downstream Modulation Alone

Blocking 5α-reductase or the androgen receptor removes or attenuates this amplifier. Residual ATP capacity is then able to support larger follicles for longer, producing the clinical benefits observed with these drugs. Yet the upstream engine remains impaired. Mitochondrial density, quality control, fuel flexibility, and redox balance are unaddressed. Consequently:

Benefits typically plateau; full restoration of pre-miniaturization phenotype is uncommon.

Systemic androgen disruption can produce sexual, mood, and metabolic side effects because the same signaling axis that is being suppressed still carries residual physiological functions.

The underlying inflammatory and insulin-resistant state continues, sustaining other compensatory pathways and leaving the follicle vulnerable to further stress.

Rebound shedding or accelerated loss can occur if the drug is stopped, because the energy mismatch was never corrected.

In short, anti-androgen therapy manages the rate of compensatory sacrifice without restoring the capacity that would make sacrifice unnecessary.

Improvement When Metabolic Persistence Is Established First

Persistence, in the sense used across these metabolic hypotheses, is the organism’s striving to persist and enhance its power of acting through coherent energy transformation. Establishing metabolic persistence means restoring net ATP output relative to demand via the foundational inputs: species-appropriate fuel (animal proteins and fats plus fermented microbiota-accessible carbohydrates), circadian entrainment, and progressive dynamic resistance loading. When this is achieved first, several beneficial shifts occur:

Normalization of the androgen milieu from above. Improved insulin sensitivity may raise SHBG, lower free androgen fractions, and reduces adrenal/ovarian over-production driven by hyperinsulinemia and inflammation. Local follicular DHT exposure declines without pharmacological blockade.

Increased follicular energy headroom. Higher mitochondrial capacity allows the follicle to meet the ATP cost of a full terminal phenotype even in the presence of residual genetic androgen sensitivity. The same DHT signal that previously triggered miniaturization now encounters a cell population better able to resist it.

Reduced inflammatory amplification. Lower mtDAMP signaling and systemic inflammatory tone diminish the co-factors that make androgen receptor signaling more destructive.

Synergistic response to residual anti-androgen therapy. If genetic predisposition still warrants pharmacological support, the hypothesis predicts that lower doses or intermittent use may suffice. Side-effect burden may decrease because the systemic hormonal axis is no longer operating in chronic compensatory overdrive. Quality metrics (diameter, pigmentation, tensile strength) improve more robustly because the energetic substrate for keratin and melanin synthesis has been restored.

Shift in therapeutic goal. The primary objective becomes preservation and enhancement of the honest signal through surplus capacity rather than perpetual suppression of a compensatory pathway. Anti-androgen agents, when used, become temporary or adjunctive tools rather than lifelong necessities.

Dr. Zudans’s clinical impressions, not yet confirmed in trials, point in this direction. Patients with androgenetic alopecia who concurrently improve insulin sensitivity, reduce visceral adiposity, and raise markers of mitochondrial function (grip strength, VO₂ kinetics, inflammatory indices) may report better stabilization and quality gains than androgen modulation alone would predict. The reverse sequence—aggressive anti-androgen therapy without metabolic restoration—leaves the underlying mismatch intact and often requires escalating intervention.

In the metabolic philosophy of medicine, therefore, androgen modulation is not dismissed; it is repositioned. It is a legitimate downstream intervention for an amplifier of energy triage. Its safety, efficacy, and durability are predicted to improve substantially when the primary constraint—ATP supply relative to demand—is first addressed and the organism’s persistence is restored. The follicle then requires less forced downsizing because it can again afford the costly phenotype that natural selection has long used as a visible index of metabolic fitness.

Downstream Load Amplifiers: Retinoids and Energy-Intensive Resurfacing

Retinoids and laser resurfacing fit the same pattern as androgen modulation: they are downstream interventions that increase cellular demand or force remodeling without restoring the upstream ATP-generating capacity that must support those processes.

Retinoids as Load Amplifiers

Topical retinoids (tretinoin and related agents) accelerate keratinocyte turnover, promote dermal fibroblast activity, increase collagen and glycosaminoglycan synthesis, and normalize some aspects of photoaged epidermis. These are energetically expensive processes. Keratinocytes and fibroblasts already operate near the edge of their capacity under chronic mitochondrial constraint; forcing higher proliferative and synthetic rates raises ATP and reducing-power demand.

When the engine is underpowered, the hypothesis predicts several consequences. Local energy shortfall manifests as irritation, barrier disruption, dryness, and retinoid dermatitis—the classic “retinization” period may be the tissue’s expression of insufficient capacity to meet the new load. Collagen production may increase transiently, yet the quality and durability of that matrix remain limited if mitochondrial redox balance and substrate supply are inadequate. Advanced glycation and incomplete cross-linking can still occur. On this hypothesis, long-term structural gains plateau because the same fibroblasts that are being driven harder continue to suffer from impaired mitophagy, reduced biogenesis, and chronic low-grade inflammation.

In metabolic terms, retinoids do not correct the mismatch between ATP supply and demand; they raise demand. The visible improvement in texture and fine lines is real, but it is achieved by pushing a constrained system harder rather than by expanding its capacity. The same logic that applies to anti-androgen therapy applies here: the intervention can be useful, yet its tolerability, magnitude of benefit, and durability are predicted to improve substantially once metabolic persistence is restored and the tissue can meet the increased turnover load without compensatory stress responses.

Laser Resurfacing as Controlled Energetic Injury

Ablative and non-ablative lasers create controlled thermal damage that triggers a wound-healing cascade—inflammation, fibroblast activation, neocollagenesis, and epidermal renewal. This is an acute, high-energy demand state. Successful remodeling requires adequate ATP for cell proliferation and protein synthesis, robust redox buffering to manage the ROS burst of injury and repair, sufficient mitochondrial quality control so that damaged organelles do not propagate inflammatory signaling, and nutrient and hormonal support for the anabolic phase of healing.

When mitochondrial capacity is already limited, the same injury can produce prolonged inflammation, delayed re-epithelialization, suboptimal collagen organization, or higher risk of scarring and dyspigmentation. The laser does not “fix” the aging phenotype; it imposes a temporary high-load state and relies on the tissue’s residual capacity to rebuild. If that capacity is constrained, the rebuild is incomplete or metabolically costly.

Integration with the Metabolic Framework

Both retinoids and laser resurfacing are therefore best understood as amplifiers of a desired phenotypic program (higher turnover, forced remodeling) rather than restorers of the energetic conditions that make those programs sustainable. They sit downstream of the primary constraint—progressive loss of ATP-generating capacity—just as androgen signaling does in the follicle.

Establishing metabolic persistence first changes the risk–benefit equation in parallel ways. Higher baseline mitochondrial density and fuel flexibility allow keratinocytes and fibroblasts to meet the increased demand of retinoid-driven turnover or post-laser repair with less relative energy deficit. Improved insulin sensitivity, lower chronic inflammation, and better redox status reduce the likelihood of irritation, prolonged erythema, or dysregulated healing. The magnitude and durability of structural improvement increase because the newly synthesized matrix is produced by cells that can sustain higher energetic output. Lower doses or less aggressive laser parameters may suffice, reducing side-effect burden.

In the context of hair, the same principle applies if retinoids are used on the scalp (off-label attempts to influence follicle cycling or sebum). Accelerating turnover or altering the local milieu without restoring follicular energy capacity risks increasing load on already compromised units.

The broader pattern across dermatology is consistent: many high-efficacy interventions work by modulating downstream compensatory or homeostatic pathways (androgen signaling, epidermal turnover rate, controlled injury-repair). They produce real phenotypic change. Yet they leave the upstream engine unaddressed and can increase the energetic tax on tissue that is already operating under constraint. The metabolic philosophy of medicine does not reject these tools; it repositions them. Their optimal use occurs after, or concurrent with, restoration of surplus ATP-generating capacity so that the tissue can afford the higher performance being demanded of it.

Immune Modulation as Downstream Dashboard Control

Corticosteroids and other immune modulators used for chronic dermatologic conditions follow the identical pattern. In the metabolic framework they are downstream dashboard interventions directed at compensatory inflammatory and immune pathways that arise when cellular energy capacity is chronically insufficient. They do not restore the upstream ATP-generating capacity that would reduce the need for those compensatory responses in the first place.

How Chronic Inflammation and Autoimmunity Function as Compensation

When mitochondrial ATP output falls relative to demand, several interlocking consequences appear in skin and follicular units. Impaired barrier lipid synthesis and keratinocyte differentiation increase antigen penetration and innate immune activation. Mitochondrial damage-associated molecular patterns (mtDAMPs) leak and trigger innate immune signaling, including NLRP3 inflammasome and NF-κB pathways. Local redox imbalance and pseudo-hypoxic signaling further amplify cytokine production (IL-1, IL-6, TNF, IL-17, IL-23, type I interferons, and related mediators). Melanocytes and follicular stem cells under energetic stress become more visible to immune surveillance or more prone to autoimmune targeting.

The resulting chronic or recurrent inflammatory state—atopic dermatitis, psoriasis, alopecia areata, lichenoid disorders, rosacea flares, and related conditions—is therefore, on this hypothesis, often a secondary, compensatory response to an underlying energy shortfall rather than a primary “immune dysregulation” independent of cellular bioenergetics. The immune system is attempting to manage stressed or damaged tissue; the tissue remains stressed because the engine has not been repaired.

Steroids and Targeted Immunomodulators as Dashboard Controls

Topical and systemic corticosteroids broadly suppress this inflammatory cascade. They reduce cytokine transcription, impair leukocyte trafficking, and decrease vascular permeability. Newer agents (biologics against IL-17, IL-23, or TNF; JAK inhibitors; and related targeted therapies) more selectively interrupt specific cytokine nodes. Both classes can produce rapid and often dramatic clinical improvement.

Yet they leave the primary constraint unaddressed. The mitochondrial deficit, insulin resistance, and chronic redox strain continue. Barrier and cellular resilience remain impaired, so the inflammatory drive reasserts when the drug is tapered. Corticosteroids themselves exert catabolic effects—impaired collagen synthesis, skin atrophy, delayed healing—that further tax an already energy-limited tissue. Systemic immune modulation carries risks of infection, metabolic disruption, and other off-target effects precisely because the organism is being forced to operate with a suppressed compensatory system while the underlying energetic mismatch persists.

In short, these agents manage the rate and intensity of the compensatory inflammatory response without restoring the capacity that would make the compensation less necessary.

Improvement When Metabolic Persistence Is Established First

Restoring net ATP output relative to demand changes the equation in the same way it does for androgen modulation, retinoids, and energy-intensive resurfacing. Improved mitochondrial function and lower mtDAMP release reduce the primary triggers of inflammasome and innate immune activation. Better insulin sensitivity and lower chronic inflammatory tone decrease the systemic amplification of local skin signals. Enhanced barrier lipid synthesis and keratinocyte energy capacity improve physical and chemical barrier integrity, reducing antigen-driven immune stimulation. Fibroblasts and stem-cell niches regain capacity for orderly repair rather than chronic low-grade injury-repair cycling.

Under these conditions the inflammatory set-point is predicted to fall. Consequently, lower-potency or less frequent topical steroids may suffice; duration of systemic or biologic therapy may be shortened; rebound flares may become less severe or less frequent; and the overall risk–benefit of any remaining immunomodulation may improve because the tissue is no longer in chronic compensatory overdrive. These are predictions not yet tested in trials; any change in dose or duration belongs with the prescribing physician.

Dr. Zudans’s clinical impressions, not yet confirmed in trials, are consistent with this sequencing. Patients whose metabolic markers (insulin sensitivity, inflammatory indices, body composition, grip strength, sleep and circadian alignment) improve may experience better disease control and reduced medication dependence even when formal immunosuppressive regimens are held constant or tapered. The reverse sequence—aggressive, prolonged immune suppression without metabolic restoration—may produce temporary clearance followed by recurrence and cumulative treatment burden.

Position within the Metabolic Philosophy of Medicine

Corticosteroids and targeted immune modulators are therefore not rejected. They are repositioned as legitimate, sometimes essential, tools for controlling downstream compensatory inflammation. Their optimal deployment occurs after, or concurrent with, restoration of surplus ATP-generating capacity. When the engine can again meet tissue demand, the need for continuous dashboard suppression diminishes, side-effect exposure falls, and the durability of clinical remission rises.

This completes a consistent pattern across major dermatologic interventions:

Androgen modulation suppresses a hormonal amplifier of energy triage.

Retinoids and laser increase cellular demand or force remodeling without expanding capacity.

Steroids and immune modulators suppress the inflammatory consequences of energy shortfall without correcting the shortfall.

In each case the intervention can be useful. In each case its safety, efficacy, and durability are predicted to improve once metabolic persistence is restored and the tissue can afford the phenotype being demanded of it.

Skin Cancer

The same energy hierarchy that produces graying, thinning, barrier failure, and inflammatory dermatoses reaches its most consequential expression in neoplastic transformation. On this hypothesis, skin cancer is not a separate category of disease driven by random genetic hits in isolation. It is the logical endpoint of chronic mismatch between ATP-generating capacity and cellular load, expressed through the same two-step process that organizes the mitochondrial-metabolic hypothesis of cancer.

The Two-Step Process Applied to the Integument

Step one is the primary cellular energy crisis. In keratinocytes and melanocytes subjected to cumulative ultraviolet load, aging-related mitochondrial decline, insulin resistance, chronic low-grade inflammation, or other sources of bioenergetic strain, oxidative phosphorylation falters. ATP output falls relative to the high demand of DNA repair, barrier maintenance, pigment production, and orderly differentiation. The cell initiates a primitive glycolysis rescue program—an ancestral survival response that prioritizes rapid carbon acquisition and biomass production over efficient oxidative metabolism. This is the Warburg-like shift. It is not yet cancer; it is a stressed cell operating under metabolic constraint.

Step two is natural selection within the resulting heterogeneous population. The glycolysis-rescued cells generate elevated mtROS, replication stress, and genomic instability as secondary consequences. Mutations arise and are retained when they enhance carbon efficiency, apoptosis resistance, immune evasion, or invasive capacity. Subclones optimized for the primitive metabolic state outcompete their more cooperative neighbors. Over successive generations the population locks into the full neoplastic phenotype. Genetic alterations are real and clinically important, yet they are downstream amplifiers and selectable advantages created by the upstream energy crisis, not the originating cause. Against this reading, melanomas carry among the highest mutation loads of any cancer, dominated by the ultraviolet-damage signature, with recurrent driver mutations such as BRAF and NRAS.

Precancerous Lesions as Visible Intermediate Stages

Precancerous skin lesions—actinic keratoses, squamous dysplasia, atypical and dysplastic nevi, and related entities—are the clinically and histologically visible intermediate stages of this two-step process. They represent populations of keratinocytes or melanocytes that have already executed the first step (glycolysis rescue under energetic constraint) but have not yet completed the second step (full selective locking of an invasive, apoptosis-resistant clone).

Histologically these lesions display disordered architecture, atypical nuclei, and metabolic signatures consistent with bioenergetic stress and compensatory glycolysis. Clinically they are the field of damaged, energy-compromised tissue from which invasive squamous cell carcinoma, basal cell carcinoma, and melanoma preferentially arise. On this hypothesis, their prevalence tracks the same metabolic risk factors that accelerate graying, thinning, and chronic inflammatory dermatoses: cumulative solar damage layered on systemic mitochondrial decline, obesity, insulin resistance, and aging. The established drivers are cumulative sun exposure, fair skin, age, and immunosuppression; links to obesity and insulin resistance are less established. They are not random “pre-cancer” in a purely genetic sense; they are the integument’s visible map of where the first step of the two-step process has already occurred and where selective pressure continues to operate.

This framing has immediate practical implication. Destruction or excision of individual actinic keratoses or dysplastic nevi removes the current visible lesion but does not restore the upstream ATP-generating capacity of the surrounding field or of the organism. The selective landscape that favors further progression remains intact. New lesions continue to appear, and the residual risk of invasive transformation persists until metabolic persistence is restored.

Late Metastatic Recurrence of Melanoma as Signal of Failed Restoration

Melanoma provides the clearest clinical illustration of the limits of local intervention without metabolic restoration. Wide local excision, sentinel-node biopsy, and, when indicated, adjuvant immunotherapy or targeted therapy can achieve apparent disease-free status. Yet late metastatic recurrence—sometimes years after the primary lesion has been removed—remains a persistent and often fatal reality.

Within the metabolic hypothesis this pattern is expected. Excision removes the dominant clone but does not correct the systemic and local energy crisis that selected for that clone in the first place. Residual microscopic disease, circulating tumor cells, or new field-transformed melanocytes continue to experience the same selective pressure: limited ATP capacity, elevated insulin/IGF signaling, chronic inflammatory tone, and a microenvironment that continues to favor glycolysis-optimized, apoptosis-resistant phenotypes. When the organism’s persistence remains unrestored, these residual or nascent populations eventually expand into clinically detectable metastases.

The recurrence is therefore not merely “bad luck” or incomplete surgical margins. It is a signal that the upstream constraint was never lifted. Local control without restoration of surplus mitochondrial capacity leaves the selective landscape intact; the two-step process continues in the residual tissue and in distant niches. Conversely, patients who achieve durable systemic metabolic improvement—restored insulin sensitivity, reduced visceral adiposity, higher markers of mitochondrial function, and lower chronic inflammatory set-points—may create an environment less hospitable to the continued selection and expansion of residual neoplastic clones. The hypothesis predicts that metabolic restoration concurrent with or following definitive local therapy should reduce late recurrence risk beyond what local control alone can achieve.

Position of Skin Cancer within the Dermatologic Hierarchy

Skin cancer thus completes the continuum already mapped for hair and non-neoplastic skin disease. Graying and thinning represent early, reversible load-shedding. Inflammatory and autoimmune dermatoses represent intermediate compensatory immune activation against energy-stressed cells. Precancerous lesions represent the first step of the two-step neoplastic process made visible. Invasive carcinoma and melanoma represent completion of selective locking. Late metastatic recurrence after apparent local cure represents the continued operation of that selective process in an organism whose metabolic persistence was never restored.

In each case the therapeutic priority remains the same: restore surplus ATP-generating capacity so that the tissue can again afford cooperative, high-fidelity function rather than being forced into triage, inflammation, or primitive survival programs. Surgery, destruction, targeted therapy, and immunotherapy remain essential tools for controlling existing neoplastic populations. Their durability and the prevention of new or recurrent disease, however, are predicted to improve when the engine that selected for those populations is repaired.

Photobiomodulation and Hormetic Light: Ancestral Mitochondrial Stimulus

The Circadian pillar of metabolic restoration is not limited to sleep timing and blue-light entrainment of the master clock. It includes the full spectral and temporal pattern of sunlight as a direct mitochondrial stimulus. Photobiomodulation—whether from natural sunlight or from carefully dosed red and near-infrared devices—is thought to act on cytochrome c oxidase (Complex IV of the electron transport chain). Photon absorption dissociates inhibitory nitric oxide, increases electron flux, elevates ATP production, and generates a controlled, hormetic rise in reactive oxygen species that activates adaptive antioxidant and biogenesis pathways. On this hypothesis, the net effect is an expansion of cellular energy headroom precisely where the metabolic hypothesis requires it: in melanocytes, keratinocytes, fibroblasts, and follicular stem-cell niches.

Sunlight is the original and most complete photobiomodulation source. Its spectral composition changes predictably with solar angle. At high solar elevations (midday) the absolute intensity of ultraviolet radiation is highest and the UV fraction relative to total irradiance is greatest; this is the period of maximal vitamin D synthesis potential and also maximal DNA-damage load if exposure is prolonged. At low solar elevations (morning and evening) the longer atmospheric path preferentially scatters and absorbs shorter wavelengths, so the direct beam becomes relatively richer in red and near-infrared light. These longer wavelengths penetrate to dermal and follicular depths and deliver the cytochrome-c-oxidase stimulus with lower concurrent UV burden. The ancestral pattern therefore supplied a daily sequence: morning and late-day red/NIR-dominant mitochondrial input, midday UV-dominant vitamin D and circadian reinforcement, all within a total dose that remained inside the organism’s evolved hormetic window.

The therapeutic goal is matching this pattern rather than maximization or minimization. Chronic under-exposure (indoor living, total sun avoidance) deprives mitochondria of a primary biogenic and ATP-enhancing input and eliminates the vitamin D signal. Chronic over-exposure (repeated burning or prolonged high-UV load without recovery) imposes DNA damage and oxidative stress that exceed repair capacity, driving the first step of the two-step carcinogenic process and accelerating the very energy crisis the hypothesis seeks to reverse. The hormetic window—non-burning, time-of-day-appropriate exposure calibrated to skin type, latitude, and season—supplies the mitochondrial stimulus while remaining within tolerance.

Sunscreen, the “Zero-Exposure” Ideal, and the Paradox

Conventional dermatologic guidance has long treated any unprotected ultraviolet exposure as inherently harmful and has promoted near-complete avoidance or continuous high-SPF coverage as the ideal. Observational studies have repeatedly shown that frequent sunscreen users have higher rates of melanoma and non-melanoma skin cancer—the so-called sunscreen paradox. This association is real but almost certainly confounded: individuals who apply sunscreen more often also tend to spend more total time in high-UV environments under a false sense of security, frequently fail to reapply, and may already carry higher cumulative damage or genetic risk; in one randomized trial, holiday-makers given higher-SPF sunscreen sunbathed longer. Randomized trials of consistent, proper daily application (notably the Nambour trial) reported reductions in squamous-cell carcinoma and, in long-term follow-up, melanoma incidence. The paradox therefore does not prove that sunscreen causes cancer; it illustrates that imperfect real-world use can increase net UV dose.

The deeper problem lies in the zero-exposure ideal itself. Complete avoidance removes the hormetic mitochondrial and vitamin D signals that the metabolic hypothesis regards as upstream inputs. Chemical (organic) UV filters such as oxybenzone, octinoxate, and related compounds are absorbed systemically and show endocrine activity in high-dose animal models; human relevance at typical exposure levels remains uncertain but is a legitimate concern for chronic use. Mineral (physical) blockers—non-nano zinc oxide and titanium dioxide—remain on the surface, reflect and scatter UV, and have a more favorable systemic-safety profile. When protection is required to prevent burns (prolonged midday exposure, fair skin, high altitude, reflective surfaces), mineral formulations are the more coherent choice within a metabolic framework. The priority, however, remains dose titration rather than universal blockade: allow non-burning exposure in the ancestral spectral windows, reserve sunscreen for situations that would otherwise exceed the individual’s current tolerance, and prefer mineral agents when protection is needed. This is the hypothesis’s preference, not tested guidance; in the one long-term randomized trial, regular daily sunscreen reduced squamous-cell carcinoma and melanoma, and the authors of the absorption study said their findings do not mean people should stop using sunscreen.

Sunglasses, ipRGCs, and Circadian Signaling

Sunglasses introduce a parallel issue at the level of ocular light sensing. Intrinsically photosensitive retinal ganglion cells (ipRGCs) contain the photopigment melanopsin and are maximally sensitive to short-wavelength (blue) light. These cells project to the suprachiasmatic nucleus and are important for circadian entrainment and melatonin suppression by light; morning light may also amplify the cortisol awakening response (CAR). Brief morning outdoor light exposure without sunglasses may help set a robust CAR (a small dawn-simulation study found a larger CAR), improve daytime alertness, and start the biological countdown for evening melatonin onset. Heavy attenuation of the relevant wavelengths by sunglasses during the morning window may blunt this signal.

Claims that sunglasses meaningfully increase whole-body sunburn risk by blocking ocular signals for systemic melanin production are weakly supported; melanin synthesis is primarily a local response to UV striking the skin itself. The stronger, better-established concern is disruption of circadian and HPA-axis optimization. Constant high-block eyewear, especially in the morning, is another modern habit that removes an upstream entrainment signal in the name of protection. Legitimate ocular UV risks (cortical cataract, pterygium, photokeratitis, and possibly macular contributions, though that link is inconsistent) still warrant protection during high-UV periods, particularly midday, high altitude, water, snow, or other reflective environments. The coherent approach is the same hormetic principle applied elsewhere: allow brief unfiltered morning light to reach the eyes for circadian benefit (never looking directly at the sun), use UV-blocking sunglasses and a hat when UV load would otherwise be excessive, and avoid the extreme of constant high-block eyewear in all conditions.

Astaxanthin and Mitochondrial Redox Buffering

Astaxanthin, a ketocarotenoid, offers a complementary internal strategy. It preferentially localizes to mitochondrial membranes, preserves membrane potential under oxidative challenge, keeps the mitochondrial matrix in a more reduced redox state, and supports continued respiration when Complex III is stressed, in cell studies. It is not a classical electron-transport-chain catalyst in the sense of accelerating electron flow through the complexes; rather, it stabilizes membrane integrity and redox balance so that the existing ETC can continue to function under load that would otherwise tip into excessive ROS and membrane damage. Human and animal data suggest that oral astaxanthin reduces UV-induced erythema, improves skin elasticity and moisture, and lowers markers of oxidative damage; in one industry-funded randomized trial it raised the dose of UV needed to cause redness. Within the metabolic hypothesis it may function as a targeted redox buffer that modestly raises the UV dose needed to cause redness; it is not a substitute for sun protection.

Metabolic Optimization Widens the Therapeutic Window

The same logic that applies to androgen modulation, retinoids, and immune suppression applies to solar load. An organism operating with higher baseline mitochondrial density, better fuel flexibility, lower chronic inflammation, and improved redox buffering can tolerate a larger absolute UV and oxidative burden before compensatory glycolysis rescue and mutagenic stress are triggered. Metabolic optimization therefore does not eliminate the need for intelligent exposure management; it enlarges the dose range that remains net beneficial. Grip strength, insulin sensitivity, inflammatory indices, and sleep/circadian alignment become practical proxies for how wide that individual window currently is. As capacity rises, the same midday sun that previously produced erythema may become tolerable for longer periods; as capacity falls, even modest exposure tips into damage. This is untested; reddening or burning remains a signal to cover up or get out of the sun. The practical implication is sequencing: restore persistence first, then allow progressively larger hormetic light doses, using mineral sunscreen, selective eye protection, and internal buffers such as astaxanthin only when the planned exposure would otherwise exceed the present window.

Artificial red and near-infrared devices can approximate the mitochondrial component when natural sunlight is unavailable or when targeted delivery to the scalp or face is desired. Sham-controlled trials support modest gains in hair counts with consistent use; evidence for gains in shaft diameter, dermal collagen, and inflammatory tone is less established. These devices remain adjunctive. They lack the full spectral complexity, the concurrent vitamin D and nitric-oxide signaling, and the circadian contextual cues of actual outdoor light. They are tools for closing a gap, not replacements for the ancestral pattern.

Within the metabolic hypothesis of dermatology, photobiomodulation is therefore repositioned. It is not a cosmetic gadget or an isolated “anti-aging” modality. It is one expression of the Circadian pillar: a direct, evolutionarily conserved input that expands mitochondrial ATP capacity, supports redox resilience, and helps keep cellular load within the range that permits pigment, diameter, barrier integrity, and cooperative rather than neoplastic behavior. When combined with species-appropriate fuel and progressive resistance loading, appropriately timed hormetic light exposure becomes part of the upstream restoration of persistence rather than another downstream intervention layered onto an unrepaired engine.

Implications

If hair, skin, and cutaneous neoplastic phenotypes are primarily energy-allocation decisions and selective outcomes of ATP mismatch, then the therapeutic priority is restoration of surplus ATP-generating capacity rather than perpetual cosmetic camouflage, isolated pathway blockade, or local destruction alone. The same three pillars that restore mitochondrial density, quality control, and fuel flexibility—species-appropriate fuel emphasizing animal proteins and fats plus fermented microbiota-accessible carbohydrates, circadian entrainment through light and sleep timing (including hormetic, time-of-day-matched solar exposure that respects the midday UV peak and morning/evening red-NIR enrichment, with brief unfiltered morning outdoor light to the eyes for ipRGC signaling, never looking directly at the sun), and progressive dynamic resistance loading—create the conditions under which the follicle and dermis can again afford pigmentation, diameter, density, collagen turnover, barrier integrity, orderly immune homeostasis, and cooperative multicellular behavior that resists neoplastic selection. Targeted cofactors that support electron transport or redox buffering may assist once the foundational inputs are in place; they do not substitute for them.

Early intervention yields the greatest return: pigment and diameter recovery, dermal thickening, improved barrier function, reduced inflammatory drive, and interruption of the first step of carcinogenesis are most reliable when residual melanocytes, intermediate follicles, competent fibroblasts, and non-locked precancerous fields still exist. Once the phenotype is advanced—permanent vellus conversion, stem-cell depletion, or selective locking of invasive clones—the realistic goal shifts from full restoration to stabilization, quality improvement of remaining structures, reduction of inflammatory-autoimmune acceleration, and minimization of further selective pressure favoring residual neoplastic cells. Objective tracking—serial high-resolution photography, trichoscopy for diameter and density, dermoscopic monitoring of pigmented lesions, simple metabolic markers (fasting insulin, HOMA-IR, grip strength, inflammatory indices)—distinguishes genuine plasticity and risk reduction from placebo or temporary shedding cycles.

The modern epidemic of earlier and more widespread graying, thinning, accelerated cutaneous aging, chronic inflammatory dermatoses, and rising rates of skin cancer in younger cohorts (though US melanoma incidence has recently fallen among adolescents and young adults) is therefore, on this hypothesis, less a mystery of “accelerated aging genes” or isolated immune dysregulation than a predictable consequence of population-level decline in mitochondrial performance under mismatched fuel, light, and movement inputs. The remedy is not more sophisticated mimicry of the lost signal, perpetual dashboard suppression, or ever-more-aggressive local destruction without upstream correction. It is restoration of the surplus capacity that once made the signal affordable, the compensatory responses less necessary, and the selective landscape hostile to neoplastic locking. When the engine can again meet the load, the follicle and skin resume the investments that natural selection has long used as reliable indicators of metabolic and reproductive fitness—within the limits set by remaining cellular infrastructure—and the conditions favoring the two-step process of carcinogenesis diminish.

Conclusion

Hair color, quality, and distribution, together with skin texture, barrier function, glow, and neoplastic resistance, are honest, costly signals of cellular fitness. Under chronic mismatch between ATP supply and demand, the organism systematically reduces investment in the most expensive follicular and dermal outputs, beginning with melanogenesis in the highest-demand regions and progressing to density, shaft quality, and matrix turnover. The same mismatch initiates the first step of carcinogenesis—primitive glycolysis rescue—and creates the selective conditions for the second step—locking of carbon-optimized, apoptosis-resistant clones. The resulting patterns—temples before occiput, pigment before bulk, visible skin load failure correlating with follicular failure, precancerous lesions as intermediate stages, and late melanoma recurrence after local excision—are not arbitrary. They map the hierarchy of energetic triage and the consequences of failed restoration of persistence.

Androgen signaling, retinoid-driven turnover, laser-induced remodeling, and immune modulation function as downstream amplifiers, forced-load interventions, or dashboard controls of compensatory pathways. Local destruction of precancerous and early neoplastic lesions removes the current clone but does not correct the selective landscape that produced it. Photobiomodulation, whether from ancestral solar exposure or adjunctive red/near-infrared devices, is an upstream Circadian input that expands mitochondrial capacity rather than merely modulating downstream symptoms. Conventional modulation of compensatory pathways and local control of visible disease are clinically useful yet incomplete. Their benefits, safety, and durability improve substantially when metabolic persistence is first restored, allowing the tissue to meet energetic demand rather than being forced into further downsizing, compensatory stress, continuous inflammatory suppression, or ongoing neoplastic selection.

The follicle and dermis retain substantial metabolic plasticity until critical stem-cell or structural thresholds are crossed; the neoplastic process remains interruptible until selective locking is complete. Metabolic optimization can reclaim pigment, thickness, quality, and dermal integrity within those limits, dampen the inflammatory-autoimmune amplification that drives further loss, and reduce the selective pressure that favors residual or nascent neoplastic clones. Beyond those limits the changes become permanent. The practical task is therefore to restore surplus ATP-generating capacity while the infrastructure that converts that surplus into visible hair, resilient skin, and cooperative cellular behavior still exists. In that restoration lies both healthier integument and a clearer window into the deeper metabolic coherence of the organism.

This essay synthesizes mechanistic observations in mitochondrial biology, hair-follicle and dermal physiology, clinical endocrinology, immunodermatology, photobiomodulation, sunscreen and ocular light epidemiology, and the two-step mitochondrial-metabolic hypothesis of cancer as of 2026. It is a hypothesis within the metabolic philosophy of medicine, not medical advice. Individual evaluation by a qualified physician remains essential.

Read more: Surfer · Coach · Sage (this page).

Topics in this chapter

• Androgen Modulation as Downstream Compensation
• Downstream Load Amplifiers: Retinoids and Energy-Intensive Resurfacing
• Immune Modulation as Downstream Dashboard Control
• Skin Cancer
• Photobiomodulation and Hormetic Light: Ancestral Mitochondrial Stimulus
• A Metabolic Hypothesis of Ocular Surface Disease

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.

References

1. Jones LA, Harland DP, Jarrold BB, et al., 2018. The walking dead: sequential nuclear and organelle destruction during hair development. British Journal of Dermatology 178(6):1341-1352. doi:10.1111/bjd.16148
2. Lynfield YL, MacWilliams P, 1970. Shaving and hair growth. Journal of Investigative Dermatology 55(3):170-172. doi:10.1111/1523-1747.ep12280667
3. Linch CA, 2009. Degeneration of nuclei and mitochondria in human hairs. Journal of Forensic Sciences 54(2):346-349. doi:10.1111/j.1556-4029.2008.00972.x
4. Williams R, Philpott MP, Kealey T, 1993. Metabolism of freshly isolated human hair follicles capable of hair elongation: a glutaminolytic, aerobic glycolytic tissue. Journal of Investigative Dermatology 100(6):834-840. doi:10.1111/1523-1747.ep12476744
5. Flores A, Schell J, Krall AS, et al., 2017. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology 19(9):1017-1026. doi:10.1038/ncb3575
6. Kim CS, Ding X, Allmeroth K, et al., 2020. Glutamine metabolism controls stem cell fate reversibility and long-term maintenance in the hair follicle. Cell Metabolism 32(4):629-642.e8. doi:10.1016/j.cmet.2020.08.011
7. Hamanaka RB, Glasauer A, Hoover P, et al., 2013. Mitochondrial reactive oxygen species promote epidermal differentiation and hair follicle development. Science Signaling 6(261):ra8. doi:10.1126/scisignal.2003638
8. Lemasters JJ, Ramshesh VK, Lovelace GL, et al., 2017. Compartmentation of mitochondrial and oxidative metabolism in growing hair follicles: a ring of fire. Journal of Investigative Dermatology 137(7):1434-1444. doi:10.1016/j.jid.2017.02.983
9. Misgeld T, Schwarz TL, 2017. Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron 96(3):651-666. doi:10.1016/j.neuron.2017.09.055
10. Trotter M, 1928. Hair growth and shaving. The Anatomical Record 37(4):373-379. doi:10.1002/ar.1090370405
11. Gavazzoni Dias MF, 2015. Hair cosmetics: an overview. International Journal of Trichology 7(1):2-15. doi:10.4103/0974-7753.153450
12. Wood JM, Decker H, Hartmann H, et al., 2009. Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB Journal 23(7):2065-2075. doi:10.1096/fj.08-125435
13. Nishimura EK, Granter SR, Fisher DE, 2005. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 307(5710):720-724. doi:10.1126/science.1099593
14. Dell'Anna ML, Ottaviani M, Kovacs D, et al., 2017. Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. Scientific Reports 7(1):13663. doi:10.1038/s41598-017-13961-5
15. Zhang Q, Raoof M, Chen Y, et al., 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464(7285):104-107. doi:10.1038/nature08780
16. Matilainen V, Koskela P, Keinänen-Kiukaanniemi S, 2000. Early androgenetic alopecia as a marker of insulin resistance. Lancet 356(9236):1165-1166. doi:10.1016/S0140-6736(00)02763-X
17. Xu W, Zhang WQ, Liang X, et al., 2026. Prevalence of metabolic syndrome in patients with androgenetic alopecia: an analysis of current evidence. Frontiers in Endocrinology 17:1904726. doi:10.3389/fendo.2026.1904726
18. Trifunovic A, Wredenberg A, Falkenberg M, et al., 2004. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429(6990):417-423. doi:10.1038/nature02517
19. Singh B, Schoeb TR, Bajpai P, et al., 2018. Reversing wrinkled skin and hair loss in mice by restoring mitochondrial function. Cell Death & Disease 9(7):735. doi:10.1038/s41419-018-0765-9
20. Shin H, Ryu HH, Yoon J, et al., 2015. Association of premature hair graying with family history, smoking, and obesity: a cross-sectional study. Journal of the American Academy of Dermatology 72(2):321-327. doi:10.1016/j.jaad.2014.11.008
21. Rosenberg AM, Rausser S, Ren J, et al., 2021. Quantitative mapping of human hair greying and reversal in relation to life stress. eLife 10:e67437. doi:10.7554/eLife.67437
22. Suzuki T, Chéret J, Scala FD, et al., 2023. mTORC1 activity negatively regulates human hair follicle growth and pigmentation. EMBO Reports 24(7):e56574. doi:10.15252/embr.202256574
23. Mahendiratta S, Sarma P, Kaur H, et al., 2020. Premature graying of hair: Risk factors, co-morbid conditions, pharmacotherapy and reversal-A systematic review and meta-analysis. Dermatologic Therapy 33(6):e13990. doi:10.1111/dth.13990
24. Zhou K, Wu G, Dong R, et al., 2025. Mitochondrial deoxyguanosine kinase depletion induced ROS causes melanocyte stem cell exhaustion and hair greying. Cell Regeneration 14(1):25. doi:10.1186/s13619-025-00242-0
25. Wang Y, Yang J, Luo Y, et al., 2025. Targeting IGF1-Induced Cellular Senescence to Rejuvenate Hair Follicle Aging. Aging Cell 24(7):e70053. doi:10.1111/acel.70053
26. Youm YH, Nguyen KY, Grant RW, et al., 2015. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nature Medicine 21(3):263-269. doi:10.1038/nm.3804
27. Lee S, Lee H, Lee CH, et al., 2019. Comorbidities in alopecia areata: a systematic review and meta-analysis. Journal of the American Academy of Dermatology 80(2):466-477.e16. doi:10.1016/j.jaad.2018.07.013
28. Chen H, Liu C, Cui S, et al., 2025. Intermittent fasting triggers interorgan communication to suppress hair follicle regeneration. Cell 188(1):157-174.e22. doi:10.1016/j.cell.2024.11.004
29. Kaufman KD, Olsen EA, Whiting D, et al., 1998. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology 39(4 Pt 1):578-589. doi:10.1016/s0190-9622(98)70007-6
30. Plymate SR, Matej LA, Jones RE, et al., 1988. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. Journal of Clinical Endocrinology and Metabolism 67(3):460-464. doi:10.1210/jcem-67-3-460
31. Inui S, Fukuzato Y, Nakajima T, et al., 2002. Androgen-inducible TGF-beta1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understand paradoxical effects of androgen on human hair growth. FASEB Journal 16(14):1967-1969. doi:10.1096/fj.02-0043fje
32. Griffiths CE, Russman AN, Majmudar G, et al., 1993. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). New England Journal of Medicine 329(8):530-535. doi:10.1056/NEJM199308193290803
33. Hengge UR, Ruzicka T, Schwartz RA, et al., 2006. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology 54(1):1-15. doi:10.1016/j.jaad.2005.01.010
34. Warburg O, 1956. On the origin of cancer cells. Science 123(3191):309-314. doi:10.1126/science.123.3191.309
35. Hodis E, Watson IR, Kryukov GV, et al., 2012. A landscape of driver mutations in melanoma. Cell 150(2):251-263. doi:10.1016/j.cell.2012.06.024
36. Alexandrov LB, Nik-Zainal S, Wedge DC, et al., 2013. Signatures of mutational processes in human cancer. Nature 500(7463):415-421. doi:10.1038/nature12477
37. Faries MB, Steen S, Ye X, et al., 2013. Late recurrence in melanoma: clinical implications of lost dormancy. Journal of the American College of Surgeons 217(1):27-34. doi:10.1016/j.jamcollsurg.2013.03.007
38. Hamblin MR, 2018. Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochemistry and Photobiology 94(2):199-212. doi:10.1111/php.12864
39. Autier P, Doré JF, Négrier S, et al., 1999. Sunscreen use and duration of sun exposure: a double-blind, randomized trial. Journal of the National Cancer Institute 91(15):1304-1309. doi:10.1093/jnci/91.15.1304
40. Green A, Williams G, Neale R, et al., 1999. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 354(9180):723-729. doi:10.1016/S0140-6736(98)12168-2
41. Green AC, Williams GM, Logan V, et al., 2011. Reduced melanoma after regular sunscreen use: randomized trial follow-up. Journal of Clinical Oncology 29(3):257-263. doi:10.1200/JCO.2010.28.7078
42. Matta MK, Florian J, Zusterzeel R, et al., 2020. Effect of sunscreen application on plasma concentration of sunscreen active ingredients: a randomized clinical trial. JAMA 323(3):256-267. doi:10.1001/jama.2019.20747
43. Mohammed YH, Holmes A, Haridass IN, et al., 2019. Support for the Safe Use of Zinc Oxide Nanoparticle Sunscreens: Lack of Skin Penetration or Cellular Toxicity after Repeated Application in Volunteers. Journal of Investigative Dermatology 139(2):308-315. doi:10.1016/j.jid.2018.08.024
44. Berson DM, Dunn FA, Takao M, 2002. Phototransduction by retinal ganglion cells that set the circadian clock. Science 295(5557):1070-1073. doi:10.1126/science.1067262
45. Thorn L, Hucklebridge F, Esgate A, et al., 2004. The effect of dawn simulation on the cortisol response to awakening in healthy participants. Psychoneuroendocrinology 29(7):925-930. doi:10.1016/j.psyneuen.2003.08.005
46. Taylor HR, West SK, Rosenthal FS, et al., 1988. Effect of ultraviolet radiation on cataract formation. New England Journal of Medicine 319(22):1429-1433. doi:10.1056/NEJM198812013192201
47. Wolf AM, Asoh S, Hiranuma H, et al., 2010. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. Journal of Nutritional Biochemistry 21(5):381-389. doi:10.1016/j.jnutbio.2009.01.011
48. Ito N, Seki S, Ueda F, 2018. The protective role of astaxanthin for UV-induced skin deterioration in healthy people: a randomized, double-blind, placebo-controlled trial. Nutrients 10(7):817. doi:10.3390/nu10070817
49. Jimenez JJ, Wikramanayake TC, Bergfeld W, et al., 2014. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. American Journal of Clinical Dermatology 15(2):115-127. doi:10.1007/s40257-013-0060-6
50. Paulson KG, Gupta D, Kim TS, et al., 2020. Age-specific incidence of melanoma in the United States. JAMA Dermatology 156(1):57-64. doi:10.1001/jamadermatol.2019.3353

Related pointers: Blue Eyes · Leprosy

See the notice at the top of this page. Working hypothesis, not medical advice.